The National Biotechnology Research and Development Agency (NBRDA) and La Shipson Pharmaceutical Ltd have concluded plans to commence local production of HIV drugs by the first quarter of 2026.
This was disclosed in a statement on Thursday in Abuja by Mrs. Toyin Omozuwa, Press Secretary to Prof. Abdullahi Mustapha, Director-General of NBRDA.
According to her, the move followed the recent signing of a Memorandum of Understanding (MoU) between the two parties.
She said a delegation from La Shipson Pharmaceutical Ltd, led by its Chief Executive Officer (CEO), Moses Shipi, visited NBRDA during the week for further engagements aimed at finalising preparations for the project.
“The project, which will be domiciled at NBRDA, is expected to bridge the healthcare gap created by the withdrawal of international aid for HIV treatments. It will also improve access to life-saving medicines, create jobs, drive technology transfer, and upgrade NBRDA’s laboratory infrastructure,” Omozuwa stated.
She added that the initiative would further strengthen staff capacity through expanded research and analysis, while attracting strong support from partners and investors who accompanied the delegation.
